ARUP LABORATORIES | aruplab.com

500 Chipeta Way, Salt Lake City, Utah 84108-1221 phone: 801-583-2787, toll free: 800-522-2787 Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 24 years Male

Specimen Collected: 17-Jun-24 14:	30		
HCV Quant with Reflex to HCV HR Genotype	Received: 17-Jun-24	14:33	Report/Verified: 17-Jun-24 14:42
Procedure HCV Qnt by NAAT (IU/mL) HCV Qnt by NAAT (log IU/mL)	Result 46,000 4.66 ^{f1}	Units IU/mL log IU/mL	Reference Interval
HCV Qnt by NAAT Interp	Detected * ⁱ¹		[Not Detected]
Hepatitis C High Resolution Genotyping	Received: 17-Jun-24	14:33	Report/Verified: 18-Jun-24 10:07
Procedure Hepatitis C High-Res Genotype Seq	Result by 6a ⁱ²	Units	Reference Interval

Result Footnote

f1: HCV Qnt by NAAT (log IU/mL)

Hepatitis C Virus High-Resolution Genotype by Sequencing added.

Test Information

i1: HCV Qnt by NAAT Interp INTERPRETIVE INFORMATION: HCV by Quantitative NAAT

The quantitative range of this test is 15-100,000,000 IU/mL (1.18-8.0 log IU/mL).

A result of "Not Detected" does not rule out the presence of inhibitors in the patient specimen or hepatitis C virus RNA concentrations below the level of detection of the test. Care should be taken when interpreting any single viral load determination.

This test is intended for use as an aid in the diagnosis of HCV infection in the following populations: individuals with antibody evidence of HCV with evidence of liver disease, individuals suspected to be actively infected with HCV antibody evidence, and individuals at risk for HCV infection with antibodies to HCV. Detection of HCV RNA indicates that the virus is replicating and therefore is evidence of active infection.

This test is also intended for use as an aid in the management of patients with an HCV infection undergoing antiviral therapy. The assay can be used to measure HCV RNA levels at baseline, during treatment, at the end of treatment, and at the end of follow-up of treatment to determine sustained or nonsustained viral response. The results must be interpreted within the context of all relevant clinical and laboratory findings.

This test should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular tissue-based products (HCT/P).

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at: ARUP Laboratories 500 Chipeta Way, Salt Lake City, UT 84108 Laboratory Director: Jonathan R. Genzen, MD, PhD
 ARUP Accession:
 24-169-900125

 Report Request ID:
 19476906

 Printed:
 18-Jun-24 10:08

 Page 1 of 2

Patient Age/Sex: 24 years Male

Test Information

i2: Hepatitis C High-Res Genotype by Seq INTERPRETIVE INFORMATION: Hepatitis C High Resolution Genotype

> Hepatitis C viral RNA is assayed using reverse transcription polymerase chain reaction (RT-PCR) to amplify specific portions of both the core and NS5B regions of the viral genome. The amplified nucleic acid is sequenced bidirectionally using dye-terminator chemistry (ABI). Sequencing data is compared to a database of characterized sequences.

Isolates of hepatitis C virus are grouped into six major genotypes (1-6). These genotypes are subtyped according to sequence characteristics. Sequencing both the core and NS5B regions allows for subtyping of all confirmed and most provisional genotypes, including differentiation of 1a from 1b and typing of genotype 6.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at: ARUP Laboratories 500 Chipeta Way, Salt Lake City, UT 84108 Laboratory Director: Jonathan R. Genzen, MD, PhD
 ARUP Accession:
 24-169-900125

 Report Request ID:
 19476906

 Printed:
 18-Jun-24 10:08

 Page 2 of 2